SCHEMBL2467982

SCHEMBL2467982

CCc1ccc(CCNC(=O)C2(Cc3ccccc3)CCN(C(=O)CN(C)C)CC2)cc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
ALDH1A1 P00352 7/20 0.41
FKBP1A P62942 1/20 0.41
RAB9A P51151 3/20 0.40
TACR1 P25103 2/20 0.40
LMNA P02545 1/20 0.40
TACR3 P29371 1/20 0.40
CHRM5 P08912 1/20 0.39
CHRM3 P20309 1/20 0.39
NPC1 O15118 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
HPGD P15428 1/20 0.39
KDM4E B2RXH2 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
EPHX1 P07099 1/20 0.39
EPHX2 P34913 1/20 0.39
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2471735 0.89 NPC1 (0.49) MEN1KMT2AALDH1A1FKBP1ALMNA
SCHEMBL2470205 0.89 ALDH1A1 (0.51) MEN1KMT2AALDH1A1FKBP1ARAB9A
SCHEMBL2470362 0.87 CYP2D6 (0.45) MEN1KMT2AALDH1A1FKBP1ARAB9A
SCHEMBL2467308 0.87 KMT2A (0.42) MEN1KMT2AALDH1A1FKBP1ARAB9A
SCHEMBL2471827 0.87 ALDH1A1 (0.45) MEN1KMT2AALDH1A1FKBP1ALMNA
SCHEMBL2469565 0.87 CYP2D6 (0.50) MEN1KMT2AALDH1A1LMNACHRM5
SCHEMBL2471483 0.85 ALDH1A1 (0.55) MEN1KMT2AALDH1A1FKBP1ARAB9A
SCHEMBL2473963 0.85 ALDH1A1 (0.47) MEN1KMT2AALDH1A1RAB9ALMNA
SCHEMBL2468347 0.85 ALDH1A1 (0.55) MEN1KMT2AALDH1A1FKBP1ATACR1
SCHEMBL2470199 0.85 GFER (0.50) MEN1KMT2AALDH1A1FKBP1ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2371366-A1 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-7582654-B2 Heterocyclo inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-01 US disclosed
US-7582654-B2 Heterocyclo inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNH2, KCNQ5 MEN1 3501/4885KMT2A 957/4885ALDH1A1 3941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.